Cargando…

Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer

Studies have shown cell-free microRNA (miRNA) circulating in the serum and plasma with specific expression in cancer, indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy. This study was to investigate whether plasma miRNA-21 (miR-21) can be used as a biomarker for...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Juan, Gao, Wen, Zhu, Cheng-Jun, Liu, Yi-Qian, Mei, Zhu, Cheng, Ting, Shu, Yong-Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013415/
https://www.ncbi.nlm.nih.gov/pubmed/21627863
http://dx.doi.org/10.5732/cjc.010.10522
_version_ 1782315046856032256
author Wei, Juan
Gao, Wen
Zhu, Cheng-Jun
Liu, Yi-Qian
Mei, Zhu
Cheng, Ting
Shu, Yong-Qian
author_facet Wei, Juan
Gao, Wen
Zhu, Cheng-Jun
Liu, Yi-Qian
Mei, Zhu
Cheng, Ting
Shu, Yong-Qian
author_sort Wei, Juan
collection PubMed
description Studies have shown cell-free microRNA (miRNA) circulating in the serum and plasma with specific expression in cancer, indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy. This study was to investigate whether plasma miRNA-21 (miR-21) can be used as a biomarker for the early detection of non–small cell lung cancer (NSCLC) and to explore its association with clinicopathologic features and sensitivity to platinum-based chemotherapy. We used real-time RT-PCR to investigate the expression of miR-21 in the plasma of 63 NSCLC patients and 30 healthy controls and correlated the findings with early diagnosis, pathologic parameters, and treatment. Thirty-five patients (stages NIB and IV) were evaluable for chemotherapeutic responses: 11 had partial response (PR); 24 had stable and progressive disease (SD+ PD). Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05). This marker yielded a receiver operating characteristic (ROC) curve area of 0.775 (95% CI: 0.681 – 0.868) with 76.2% sensitivity and 70.0% specificity. Importantly, miR-21 plasma levels in PR samples were several folds lower than that in SD plus PD samples (P = 0.049), and were close to that in healthy controls (P = 0.130). Plasma miR-21 can serve as a circulating tumor biomarker for the early diagnosis of NSCLC and is related to the sensitivity to platinum-base chemotherapy.
format Online
Article
Text
id pubmed-4013415
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Sun Yat-sen University Cancer Center
record_format MEDLINE/PubMed
spelling pubmed-40134152014-05-15 Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer Wei, Juan Gao, Wen Zhu, Cheng-Jun Liu, Yi-Qian Mei, Zhu Cheng, Ting Shu, Yong-Qian Chin J Cancer Original Article Studies have shown cell-free microRNA (miRNA) circulating in the serum and plasma with specific expression in cancer, indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy. This study was to investigate whether plasma miRNA-21 (miR-21) can be used as a biomarker for the early detection of non–small cell lung cancer (NSCLC) and to explore its association with clinicopathologic features and sensitivity to platinum-based chemotherapy. We used real-time RT-PCR to investigate the expression of miR-21 in the plasma of 63 NSCLC patients and 30 healthy controls and correlated the findings with early diagnosis, pathologic parameters, and treatment. Thirty-five patients (stages NIB and IV) were evaluable for chemotherapeutic responses: 11 had partial response (PR); 24 had stable and progressive disease (SD+ PD). Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05). This marker yielded a receiver operating characteristic (ROC) curve area of 0.775 (95% CI: 0.681 – 0.868) with 76.2% sensitivity and 70.0% specificity. Importantly, miR-21 plasma levels in PR samples were several folds lower than that in SD plus PD samples (P = 0.049), and were close to that in healthy controls (P = 0.130). Plasma miR-21 can serve as a circulating tumor biomarker for the early diagnosis of NSCLC and is related to the sensitivity to platinum-base chemotherapy. Sun Yat-sen University Cancer Center 2011-06 /pmc/articles/PMC4013415/ /pubmed/21627863 http://dx.doi.org/10.5732/cjc.010.10522 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.
spellingShingle Original Article
Wei, Juan
Gao, Wen
Zhu, Cheng-Jun
Liu, Yi-Qian
Mei, Zhu
Cheng, Ting
Shu, Yong-Qian
Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
title Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
title_full Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
title_fullStr Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
title_full_unstemmed Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
title_short Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
title_sort identification of plasma microrna-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013415/
https://www.ncbi.nlm.nih.gov/pubmed/21627863
http://dx.doi.org/10.5732/cjc.010.10522
work_keys_str_mv AT weijuan identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer
AT gaowen identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer
AT zhuchengjun identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer
AT liuyiqian identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer
AT meizhu identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer
AT chengting identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer
AT shuyongqian identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer